• 
  Simon Baldacci, Benjamin Besse, Virginie Avrillon, Bertrand Mennecier, Julien Mazieres, et al.. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer, 2022, 166, pp.51-59. ⟨10.1016/j.ejca.2022.01.018⟩. ⟨hal-04728569⟩
• 
  Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
• 
  Noémie Huchet, Nicolas Penel, Sylvie Bonvalot, Juliette Thariat, Françoise Ducimetière, et al.. Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF). Therapeutic Advances in Medical Oncology, 2024, 16, ⟨10.1177/17588359231220999⟩. ⟨hal-04425867⟩
• 
  Joël Guigay, Hervé Le Caer, François-Régis Ferrand, Lionel Geoffrois, Esma Saada-Bouzid, et al.. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. The Lancet. Healthy longevity, 2024, 5 (6), pp.e392-e405. ⟨10.1016/S2666-7568(24)00048-5⟩. ⟨hal-04578230⟩
• 
  Lionel Perrier, Pauline Rascle, Magali Morelle, Maud Toulmonde, Dominique Ranchere Vince, et al.. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. PLoS ONE, 2018, 13 (4), pp.e0193330. ⟨10.1371/journal.pone.0193330⟩. ⟨halshs-01784301⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, et al.. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. Journal of Hematology and Oncology, 2024, 17 (1), pp.86. ⟨10.1186/s13045-024-01606-w⟩. ⟨hal-04719756⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Marco Fiore, Catherine Sarre-Lazcano, Myles Smith, Misbah Khan, Chandrajit P Raut, et al.. Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). British Journal of Surgery, 2024, 111 (5), pp.znae128. ⟨10.1093/bjs/znae128⟩. ⟨inserm-04714954⟩
• 
  Sihem Tarfi, Bouchra Badaoui, Nicolas Freynet, Margot Morabito, Jeffie Lafosse, et al.. Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state. Haematologica, 2020, 105 (4), pp.e147-e152. ⟨10.3324/haematol.2019.219782⟩. ⟨hal-04438651⟩
• 
  Mohamed Jemaà, Gwenola Manic, Gwendaline Lledo, Delphine Lissa, Christelle Reynes, et al.. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. Oncotarget, 2016, 7 (1), pp.885-901. ⟨10.18632/oncotarget.6432⟩. ⟨hal-01878017⟩
• 
  Fabienne Lesueur, Noura Mebirouk, Yue Jiao, Laure Barjhoux, Muriel Belotti, et al.. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, pp.490. ⟨10.3389/fonc.2018.00490⟩. ⟨hal-01926758⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
• 
  Diego Teyssonneau, Charles Dariane, Eric Barret, Jean Baptiste Beauval, Laurent Brureau, et al.. PARP inhibitors in prostate cancers, is it time for combinations?. Therapeutic Advances in Medical Oncology, 2024, 16, pp.17588359241242959. ⟨10.1177/17588359241242959⟩. ⟨hal-04605172⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Hélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, Julie Rondeaux, Sophie Krieger, et al.. Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System. Cancer Research, 2020, 80 (17), pp.3593-3605. ⟨10.1158/0008-5472.CAN-20-0895⟩. ⟨hal-03597164⟩
• 
  Julien Guérin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, et al.. Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International Journal of Environmental Research and Public Health, 2024, 21 (2), pp.189. ⟨10.3390/ijerph21020189⟩. ⟨inserm-04659888⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  Y. Loriot, A. Marabelle, J.P. Guégan, F.X. Danlos, B. Besse, et al.. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Annals of Oncology, 2021, 32 (11), pp.1381-1390. ⟨10.1016/j.annonc.2021.08.1748⟩. ⟨hal-04633737⟩

268

285